Idorsia Ltd
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jean-Paul Clozel
- Full Time Employees
- 1,100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Hegenheimermattweg 91 Allschwil Switzerland 4123
- IPO Date
- Jul 17, 2017
- Website
- idorsia.com
- Similar Companies
- Business
- Idorsia Ltd, a biopharmaceutical company headquartered in Allschwil, Switzerland and founded in 2017 following its demerger from Actelion, discovers, develops and commercializes small-molecule drugs targeting central nervous system disorders, cardiovascular conditions, immunology, orphan diseases and infectious diseases; key marketed products include QUVIVIQ (daridorexant), a dual orexin receptor antagonist for insomnia commercially available in the US, Germany, Italy, Switzerland, Spain, the UK, Canada, Austria, France, Sweden and Finland with approval throughout the EU, and TRYVIO (aprocitentan) in the US and JERAYGO (aprocitentan) in the EU and UK, both dual endothelin receptor antagonists for resistant hypertension in combination with other antihypertensives; the pipeline features lucerastat, a glucosylceramide synthase inhibitor for Fabry disease in Phase 3 open-label extension with kidney biopsy data expected in Q2 2025, daridorexant for pediatric insomnia in Phase 2 with readout in Q2 2026, early-stage assets such as IDOR-1117-2520 (CCR6 antagonist) for psoriasis, ACT-777991 (CXCR3 antagonist) for vitiligo and ACT-1004-1239 (ACKR3 antagonist) for progressive multiple sclerosis advancing to proof-of-concept studies, and a synthetic glycan vaccine platform including IDOR-1134-2831 for Clostridioides difficile in Phase 1 with results in mid-2026. Operations span North America, Europe and partnerships in Asia-Pacific; partnered programs include selatogrel for acute myocardial infarction and cenerimod for systemic lupus erythematosus outlicensed worldwide to Viatris in March 2024 with amended terms in February 2025 reducing Idorsia's development cost contribution by USD 100 million while retaining royalties, aprocitentan seeking new global partners after FDA approval in March 2024 and EU approval in June 2024, daridorexant licensed to Simcere for Greater China with launch in Hong Kong and to Nxera for Asia-Pacific excluding China, and other collaborations such as with the US Department of Defense for PTSD and Owkin for immuno-oncology. Recent developments encompass QUVIVIQ net sales of CHF 61 million in 2024 with expansion via partnerships like Menarini in France and Berlin-Chemie in Germany, a holistic restructuring of CHF 800 million convertible bond debt in February 2025 securing CHF 150 million new funding to extend runway into 2026, workforce reductions to 552 permanent employees by early 2025 for cost efficiency targeting commercial profitability in 2026, and ongoing prioritization of the pipeline for inflection points or out-licensing.
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript
Idorsia announces the nomination of three candidates for election to the Board of Directors
Idorsia announces management change
Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink
Idorsia Ltd (IDRSF) Q4 2025 Earnings Call Transcript
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America
Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
Nature Communications reports promising effect of Idorsia's lucerastat on kidney function in Fabry disease
Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
Idorsia's daridorexant in women during menopausal transition age with insomnia